Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis said. Kisqali was approved as a treatment for early breast cancer by the U.S. Food and Drug Administration in September, and it has been approved as a treatment for metastatic breast ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Breast cancer is the most commonly diagnosed cancer ... therapy," said Patrick Horber M.D., President, International, Novartis. "Together with the recent FDA approval and late-breaking NATALEE ...

The company will consider types of cancer, such as non-small cell lung cancer, where other anti-VEGF/PD-1 drugs have shown promise, and cancer types that could appeal to potential suitors ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter. Sales of ...

Basel, October 18, 2024 – Novartis announced today that the Committee ... growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC), at high risk of disease recurrence, including ...

significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of patients with HR+/HER2- early breast cancer 2 People with stage II or III HR+/HER2- EBC face ...

Press release. FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer. September 17, 2024. Accessed October 15, 2024. /news/media-releases/fda ...